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Abstract
Diseases associated with Chlamydia pecorum infection are a major cause of decline in
koala populations in Australia. While koalas in care can generally be treated, a vaccine is
considered the only option to effectively reduce the threat of infection and disease at the
population level. In the current study, we vaccinated 30 free-ranging koalas with a prototype
Chlamydia pecorum vaccine consisting of a recombinant chlamydial MOMP adjuvanted
with an immune stimulating complex. An additional cohort of 30 animals did not receive any
vaccine and acted as comparison controls. Animals accepted into this study were either
uninfected (Chlamydia PCR negative) at time of initial vaccination, or infected (C. pecorum
positive) at either urogenital (UGT) and/or ocular sites (Oc), but with no clinical signs of chla-
mydial disease. All koalas were vaccinated / sampled and then re-released into their natural
habitat before re-capturing and re-sampling at 6 and 12 months. All vaccinated koalas pro-
duced a strong immune response to the vaccine, as indicated by high titres of specific
plasma antibodies. The incidence of new infections in vaccinated koalas over the 12-month
period post-vaccination was slightly less than koalas in the control group, however, this was
not statistically significant. Importantly though, the vaccine was able to significantly reduce
the infectious load in animals that were Chlamydia positive at the time of vaccination. This
effect was evident at both the Oc and UGT sites and was stronger at 6 months than at 12
months post-vaccination. Finally, the vaccine was also able to reduce the number of ani-
mals that progressed to disease during the 12-month period. While the sample sizes were
small (statistically speaking), results were nonetheless striking. This study highlights the
potential for successful development of a Chlamydia vaccine for koalas in a wild setting.
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Introduction
Infections by the intracellular bacterium Chlamydia pecorum contribute to significant morbid-
ity and mortality in the koala (Phascolarctos cinereus). Disease progression can include kerato-
conjunctivitis, cystitis, reproductive disease/sterility and blindness; the progression of which, in
severe cases, can cause death. An antibiotic treatment regime is currently recommended for
mild infections [1], however for koalas affected by severe chlamydial disease, antibiotics alone
are not sufficient to cure the clinical signs [1].
In recognition that a reduction in disease may have a positive effect in the conservation of
koalas [2, 3], our group has been leading the development of a prototype C. pecorum vaccine
[4–9]. Based on studies which have shown efficacy in animal models (reviewed in Farris and
Morrison [10]), the primary component of the C. pecorum vaccine has been the recombinant
proteins derived from the chlamydial Major Outer Membrane Protein (rMOMP). rMOMP is
highly immunogenic in humans and animals and has been studied in detail as a vaccine candi-
date. In the initial studies utilizing this vaccine antigen adjuvanted with an immune stimulating
complex, we have shown that this prototype chlamydial vaccine (i) induces long-lasting spe-
cific humoral and cell-mediated immune responses in vaccinated koalas [9]; (ii) induces an
immune response that can recognize genetically distinct C. pecorum strains, a capability that
natural infection does not appear to have [6]; (iii) induces the production of specific antibodies
that are effective in neutralizing C. pecorum in vitro [9]; and (iv) does not have any apparent
deleterious effects on the health of Chlamydia-free koalas or koalas with current chlamydial
infection and/or disease [8, 11].
In the absence of an established infection challenge model for the koala, further understand-
ing of the efficacy of the vaccine for reducing the risk and impact of chlamydial infection at
both the individual and population level is limited. In the current study, we assessed the health
outcomes of a cohort of 60 koalas, including 30 animals vaccinated with the prototype Chla-
mydia vaccine within one free-ranging population in South-East Queensland (SEQ), Australia.
Vaccinated and control cohorts of animals were then released, monitored for a period of 12
months, and recaptured periodically to compare a range of health parameters between the two
groups.
Materials and Methods
ChlamydiaMOMP recombinant preparation
Purified C. pecorumMOMP from three koala C. pecorum genotypes (A, F and G) were used as
previously described by Kollipara et al. [7].
Animals and Immunizations
Animals included in the study (n = 60) were part of a larger population-wide study by the
Queensland Government Department of Transport and Main Roads (as part of the Moreton
Bay Rail Link project), conducted between 2012 and 2015 in the Moreton Bay Region, Queens-
land, Australia. Criteria for inclusion into the study were animals of breeding age (>1 year) of
either sex, with no clinical signs of chlamydial disease, as assessed during the initial capture
event by qualified wildlife veterinarians. Animals were randomly assigned to either the vacci-
nated or control (non-vaccinated) group at initial capture. The vaccinated group (n = 30)
received a three-dose regime of the vaccine via the sub-cutaneous route, given at one-month
intervals, consisting of the three rMOMP proteins as the antigens (50μg each of MOMP-G,
MOMP-A, and MOMP-F) and an Immunostimulating complex adjuvant (50μg, ISC, Zoetis
Australia [4]). Following a detailed veterinary health assessment, animals were released with a
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radio collar or anklet for tracking (Sirtrack). Animals were re-captured at 1 month, 2 months, 6
months, and 12 months for the purpose of (i) additional vaccinations for the vaccine cohort
animals only (1 month and 2 months) or (ii) detailed health checks and sampling (2, 6 and 12
months). While 30 animals were originally recruited into each group, unfortunately, only 23
vaccinated and 27 control koalas could be resampled at the six month time point due to animal
losses associated with misadventure (e.g. predation, trauma, koala movements outside of study
area, or disease). At 12 months, again, further losses had occurred and numbers were consider-
ably reduced in each cohort to 15 vaccinated and 14 control koalas.
All procedures were approved by the University of the Sunshine Coast (USC) Animal Ethics
Committee (Animal ethics number AN/A/13/80) and by the Queensland Government (Scien-
tific Purposes Permit, WISP11532912). The trial was performed under the Australian Pesti-
cides and Veterinary Medicines Authority Permit PER 7250.
Health assessments and sampling
Koalas were located by transect searching (for initial capture) or via telemetry devices (for sub-
sequent captures). The choice of capture technique (flagging vs koala trap) was based on the
following: if a koala could be safely (for koala and capture team personnel) captured using a
flagging technique (dangling a flag on a pole above the head of a koala to gently coax them to
the bottom of the tree), then the flagging technique was employed. If the safety of the koala or
koala capture team could not be assured for a conventional flagging capture, then the capture
used the koala trap, or was aborted. Veterinary assessments and sampling, while under a short
period of anesthesia, were conducted on each animal at 0, 2, 6, and 12 month time-points fol-
lowing their initial capture and veterinary examination. Koalas were anaesthetized by intra-
muscular injection (quadriceps muscle group) of alfaxalone (Alfaxan CD RTU, Jurox) at a dose
rate of approximately 3mg/kg. A 22 or 23 gauge needle was used. Minimal or no restraint was
required, and the injection was performed while the koala was in the transport cage. After
induction of general anesthesia (approximately 5 minutes in most cases) the koala was
removed from the cage and placed on the examination table. Anesthesia was maintained by
administration of an isoflurane/oxygen mix delivered by face-mask at between 1.5–2.5% vapor
pressure of isoflurane. A full veterinary physical and clinical examination was conducted in
accordance with standard veterinary procedures Ultrasound examination of the kidneys, ure-
ters, urinary bladder and the reproductive tract allowed for identification of urogenital tract
diseases including cystitis and reproductive-tract cysts in female koalas. Urinalysis was utilized
to detect possible kidney or urinary tract disorders, such as cystitis, which is also associated
with Chlamydia. Chlamydial disease scores were assessed according to the disease scoring cri-
teria outlined in detail in Wan et al. [12]. For the purposes of this study, one set of conjuncti-
val/ocular (Oc) and urogenital (UGT) swabs were collected for Chlamydia load determination
and a blood sample of up to 5mL was collected from the cephalic vein. This was used for prepa-
ration of haematology smears and separation of plasma and serum by centrifugation. During
anaesthesia and recovery koalas were constantly monitored by an experienced wildlife veteri-
nary nurse. At the completion of all veterinary procedures, volatile anaesthesia delivery was
stopped and the koala was monitored closely until it achieved sternal recumbancy. At this
point it was transferred to a transport cage until fully recovered from anaesthesia. When the
veterinary team was satisfied that the koala had recovered sufficiently to be released back into
the wild safely, it was released by field staff at the point of capture.
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Chlamydia-specific IgG plasma response
IgG response was analysed via enzyme-linked immunosorbent assays (ELISAs). ELISAs were
performed on plasma samples at 0 and 6 months as per Khan et al. [5], and served as a control
to demonstrate that vaccinated koalas produced a specific immune response to the vaccine
antigens as previously shown [5].
Chlamydia quantification
Swab samples were stored at -20°C until the DNA was extracted as described by Devereaux
et al. [13]. The extracted samples were screened for the presence of C. pecorum using a diagnos-
tic quantitative real-time PCR (RT-PCR) targeting a 204 bp fragment of the chlamydial 16S
rRNA gene. Assays were as described in Marsh et al. [14] except for the PCR mixture contain-
ing 1× QuantiTect SYBR Green PCRMaster Mix (Qiagen) and 10 μM primers [14] made up to
a final volume of 15 μl with PCR-grade water, as well as an increased initial denaturation to 15
mins at 94°C. All reactions were carried out on a Rotor-Gene Q 5-plex HRM platform
(Qiagen).
Statistical analysis
Significant differences between 0 and 6 month IgG antibody titres were evaluated with a Wil-
coxon signed-rank test. To evaluate how C. pecorum infection prevalence and loads differed
among vaccinated versus control koalas, Chi-square contingency table analyses were used to
compare the changes in C. pecorum load over time (0 vs. 6 and 0 vs. 12 months), with changes
categorized into bands as either, decreasing, stable or increasing (ΔqPCR -100, -99–99,
and 100 copies/μL respectively). These categories were chosen because small variations of up
to 100 copies/μL in qPCR can occur across assays. We conducted this analysis on the raw num-
bers of koalas within each group (which we considered a conservative analysis, given our sam-
ple size), and on the percentage of koalas in each group (which we considered a more sensitive
approach, given our sample size). We chose these conservative and sensitive approaches
because, though our results are striking, the numerical effect of koala mortalities in the field
inflated the Type-II statistical error, limiting detection of statistical significance based on raw
data alone. Where appropriate we used Markov chain Monte Carlo simulations to overcome
Chi-square statistical issues associated with expected values< 5. Analyses were conducted on
both Oc and UGT infections (see Results). All analyses were conducted using Rv3.0.2 (www.r-
project.org).
Results
Vaccine safety data
All vaccinated animals were monitored for up to 24 hours post-vaccination and given a thor-
ough veterinary health check at 2 months and thereafter at their regular 6-monthly capture
and sampling events. There were no short or longer-term adverse events reported due to
administration of the vaccine in any of the animals.
Immune response to vaccination
We used our Chlamydia ELISA to determine plasma IgG antibody levels both (i) at 0 months
and (ii) 6 months post vaccination in the vaccine group (n = 23). We found that the average
antibody titre at 6 months post-vaccination in PCR negative and PCR positive animals was sig-
nificantly greater than at 0 months (Fig 1; PCR negative p = 0.002; PCR positive p< 0.001; S1
Table) indicating that we had successfully induced a vaccination-specific immune response.
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Chlamydia prevalence
Overall, the 60 animals initially included in our study had a C. pecorum prevalence of 54% at
time of capture (as defined by C. pecorum species-specific PCR). After recruitment into the
trial, the koalas were assigned into groups consisting of: (i) animals with a current infection, as
defined by being C. pecorum PCR positive, at the Oc site (Vaccinated: n = 10; Control: n = 6);
(ii) C. pecorum PCR positive animals at the UGT site (Vaccinated: n = 8; Control: n = 13); and
(iii) animals that were C. pecorum PCR negative at either site (Vaccinated: n = 16; Control
n = 21). Some animals (Vaccinated: n = 7; Control n = 6) were necessarily included in both
groups due to the occurrence of C. pecorum positivity at both sites. At 12 months, the number
of animals remaining in each group decreased (mortality among wild koalas) to: (i) C. pecorum
PCR positive animals at the Oc site (Vaccinated: n = 7; Control: n = 4); (ii) C. pecorum PCR
positive animals at the UGT site (Vaccinated: n = 5; Control: n = 6; and (iii) C. pecorum PCR
negative animals (Vaccinated: n = 11; Control n = 10).
Fig 1. Antibody (IgG) titre response in vaccinated animals at 0 months (pre-vaccination) and 6months post-vaccination (n = 23): Mean and
standard error of IgG titre levels. P < 0.05 *; P < 0.001 **.
doi:10.1371/journal.pone.0146934.g001
Table 1. Change inChlamydia PCR load following vaccination: Percentage (and raw number calculations) of koalas that wereC. pecorum positive
at 0 months (i.e. at initial vaccination time), and then exhibited changes in theirC. percorum load between either 0 and 6months, or between 0 and
12months, post vaccination. Statistically significant effects are shown in bold. Trending (P < 0.1) results indicated with *. Grey shading represents groups
with more than expected (based on Pearson residuals) for significant results. The changes are categorized as decreasing, stable or increasing (ΔqPCR
-100, -99–99, and 100 copies/μL respectively).
Eye (0 vs. 6 months) Eye (0 vs. 12 months) UGT (0 vs. 6 months) UGT (0 vs. 12 months)
Decrease Stable Increase Decrease Stable Increase Decrease Stable Increase Decrease Stable Increase
Control 33% (2) 0% (0) 67% (4) 100% (4) 0% (0) 0% (0) 69% (9) 0% (0) 31% (4) 83% (5) 0% (0) 17% (1)
Vacc 50% (5) 40% (4) 10% (1) 71% (5) 29% (2) 0% (0) 88% (7) 12% (1) 0% (0) 100% (5) 0% (0) 0% (0)
X2 85.677 31.619 a 45.299 16.458 a
P < 0.001 (0.052 *) < 0.001 (0.496) < 0.001 (0.099*) < 0.001 (0.999)
a analysis based on 2 x 2 contingency table Chi-square owing to no individuals with decreasing loads for both control and vaccinated koala
doi:10.1371/journal.pone.0146934.t001
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Rate of new Chlamydia infections in vaccinated koalas compared to
unvaccinated controls
For this analysis we utilized the animals that were C. pecorum negative at 0 months and able to
be recaptured at 12 months. In the control group, the 12 month incidence rate at the UGT site
was 25% (two new infections in the 8 animals in this group), and 20% (2/10) at the Oc site. By
comparison, the vaccinated animals had a slightly lower 12 month incidence rate of 20% (2/10)
and 12% (1/8) at the UGT and Oc sites respectively. While the incidence rate in the vaccinated
group was lower, the group size was small and hence the difference was not statistically signifi-
cant (raw data X2 = 0.392, p> 0.999; percentage differences X2 = 2.381, p = 0.176).
Changes in Chlamydia load following vaccination
For animals that were infected (PCR positive) at the time of recruitment, we measured their
Chlamydia load by quantitative-PCR (qPCR) at 0, 6, and 12 months to evaluate the effect the
vaccine had on the level of chlamydial shedding (Table 1). For the purposes of analysis, we
grouped the animals into three categories, based on their PCR load change, whether the load
decreased, stayed stable, or increased (ΔqPCR -100, -99–99, and 100 copies/μL
respectively).
At 6 months post-vaccination, animals in the vaccine group were significantly more likely
to decrease or stabilize their chlamydial load, whereas animals in the control group were signif-
icantly more likely to increase their load (Table 1). This effect was observed as a near significant
trend (p> 0.01) using the conservative (raw) data and a significant effect based on the more
sensitive (%) data. For example, at the ocular site 90% (9/10) of vaccinated animals decreased
or stabilized their load, compared to the control group where only 33% (2/6) had decreasing or
stabilizing loads (Table 1). Similarly, at the UGT site, 100% (8/8) of animals in the vaccinated
group had decreasing or stabilizing loads compared to 69% (9/13) in the control group
(Table 1).
At 12 months, the positive vaccine effect was maintained at the UGT site with 100% (5/5) of
vaccinated animals showing a decrease in chlamydial load compared to 83% (5/6) in the con-
trol group (Table 1). We are cautious about drawing conclusions on the statistical significance
of this owing to the difference of only a single individual. However importantly, throughout
the entire study, not one animal in the vaccine group showed an increase at the UGT site. At
the Oc site at 12 months, 100% (7/7) of vaccinated animals also decreased or stabilized their
chlamydial load, although a similar trend (100% [4/4] decrease) was seen in the control group
(Table 1). Again, we are highly cautious about interpreting the statistical significance of this
based on the sample size. Overall, smaller sample sizes of koalas, owing to field mortalities,
cause us to be cautious about statistical interpretation of results at 12 months.
Progression to chlamydial disease
To investigate the impact that vaccination had on the progression of chlamydial disease, we
compared the presence and absence of disease in vaccinated and control animals. Over the 12
months of the study, only 1 of 23 (4% of koalas) vaccinated animals developed clinical signs of
chlamydial disease, whereas 4 of 27 (14.8%) control animals developed clinical disease over the
same time period. Based on percentage differences, the control and vaccinated groups were sig-
nificantly dissimilar (X2 = 7.037, p = 0.013), but the same result could not be observed in the
raw data (X2 = 1.512, p = 0.363) owing to the sample size. The one vaccinated animal developed
mild, sub-acute, chronic cystitis, was treated in care with the standard chloramphenicol dosage
and released as healthy. Three of the four animals that developed disease in the control group
A Therapeutic Anti-Chlamydial Vaccine for the Koala
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developed cystitis and were treated; the final animal developed severe and extensive reproduc-
tive disease as well as severe chronic cystitis, and was euthanized.
Discussion
We have, for the first time, examined the effect of a rMOMP based anti-chlamydial vaccine on
chlamydial infection risk and outcome in free-ranging koalas. The vaccine induced a significant
immune response in wild-caught koalas. The incidence of new C. pecorum infections was lower
at both anatomical sites in vaccinated animals, despite not being statistically significant. Impor-
tantly, we also found that vaccinated koalas were more likely to have stable or decreasing C.
pecorum PCR loads, and were also less likely to increase their chlamydial burdens at 6 months
post-vaccination at both anatomical sites. At 12 months, this positive effect could still be
observed in the vaccinated cohort, with no animals increasing their chlamydial loads at either
anatomical site. However, we caution the low number of koalas at this time point made statisti-
cal inference unreliable. Lastly, we showed a positive effect for protecting against progression
to disease in vaccinated animals.
Therapeutic vaccines are a promising new approach to enhance immunogenicity, and
reduce viral and bacterial load in infected humans and animals [15]. Due to the difficulties
associated with antibiotic treatment in the koala, a therapeutic vaccine may provide an impor-
tant alternative to reduce infection. While antibiotics are curative in many cases of chlamydial
disease, the therapeutic course is relatively long and labour intensive, often precluding its effi-
cacy for the treatment of koala outside of the clinic. Therefore, a therapeutic vaccine provides a
more practical solution for disease management at a non-captive population level, particularly
if a single-dose vaccine were to be developed. In our current study, the positive therapeutic
effect seen at both anatomical sites in the koala is a promising result for the development of a
therapeutic chlamydial vaccine for this species. The loss of meaningful statistical inference at
12 months due to severe field mortalities is disappointing, masking our ability to confidently
detect an effect at this time interval. This effect seems largely skewed by the four animals in the
control group reducing their chlamydial ocular burden. When followed longitudinally up to
two years, two of these four animals developed clinical signs of disease, whereas none of the
vaccinated animals in that cohort developed any clinical signs (unpublished data).
While we did not observe a significant improvement in the risk of new infections in the vac-
cinated koalas, it was interesting to note nevertheless that asymptomatically infected control
animals were more likely to advance to disease than asymptomatically infected vaccinated ani-
mals. Promisingly, over 12 months, only one vaccinated animal developed new disease symp-
toms (cystitis), whereas 4 animals in the non-vaccinated cohort succumbed to disease (cystitis
n = 3 and reproductive disease n = 1). While beyond the scope of this manuscript, it is also
promising to observe that available longitudinal data for the remaining animals at 18–24
months suggests that two (of 7; 28.6%) additional control animals contracted cystitis, whereas
none of the vaccinated animals has yet succumbed to disease (0/6; 0%).
To conclude, the first field trial to date of this prototype koala chlamydial vaccine suggests
that vaccinated Chlamydia-infected koalas have an improved infection outcome—an outcome
that highlights the potential for the development of a therapeutic vaccination schedule for this
species. This is especially promising given the small sample sizes, and the natural variability of
an outbred population. In the koala, the main goal for population management from an eco-
logical standpoint is maintaining health and young animal recruitment. Therefore, if a vaccine
is able to lower or prevent increases of infection load, as well as to decrease the progression to
disease, than this will have positive effects on population health and fecundity and may be an
important tool in the management and conservation of the koala.
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Supporting Information
S1 Table. Plasma IgG antibody titers of both (i) at 0 months (pre-vaccination) and (ii) 6
months post vaccination in koalas (n = 23) vaccinated with a recombinant Major Outer
Membrane Protein (MOMP) vaccine adjuvanted with an Immunostimulating complex
adjuvant (ISC).
(XLSX)
Acknowledgments
This work was funded by an Australian Research Council (ARC) Linkage Grant
(LP1202000051) awarded to PT, AP, and KB. This project was significantly supported by the
Queensland Government (Department of Transport and Main Roads) and specifically the
Moreton Bay Rail Link project team. We also thank the many groups that have supported the
overall koala Chlamydia vaccine work, including, Queensland Department of Environment
and Heritage Protection, Moreton Bay Regional Council, Friends of Koala, Lismore, Endeavour
Veterinary Ecology, Australia Zoo Wildlife Hospital, Lone Pine Koala Sanctuary, VIDO, Can-
ada. Specifically, here we thank the dedicated staff at Endeavour Veterinary Ecology for their
help in capturing, radio collars and tracking the koalas, and undertaking the health assessments
and collecting samples. We thank Zoetis Australia for the donation of the immune stimulating
complex as adjuvant.
Author Contributions
Conceived and designed the experiments: PT KB AP CW. Performed the experiments: CW
SAK. Analyzed the data: SC PT CW. Contributed reagents/materials/analysis tools: JH JL.
Wrote the paper: CW PT.
References
1. Govendir M, Hanger J, Loader JJ, Kimble B, Griffith JE, Black LA, et al. Plasma concentrations of chlor-
amphenicol after subcutaneous administration to koalas (Phascolarctos cinereus) with chlamydiosis. J
Vet Pharmacol Ther. 2012; 35: 147–54. doi: 10.1111/j.1365-2885.2011.01307.x PMID: 21569052
2. Craig AP, Hanger J, Loader J, Ellis WAH, Callaghan J, Dexter C, et al. A 5-yearChlamydia vaccination
programme could reverse disease-related koala population decline: Predictions from a mathematical
model using field data. Vaccine. 2014; 32: 4163–70. doi: 10.1016/j.vaccine.2014.05.049 PMID:
24877768
3. Rhodes JR, Ng CF, de Villiers DL, Preece HJ, McAlpine CA, PossinghamHP. Using integrated popula-
tion modelling to quantify the implications of multiple threatening processes for a rapidly declining popu-
lation. Biol Cons. 2011; 144: 1081–8.
4. Carey AJ, Timms P, Rawlinson G, Brumm J, Nilsson K, Harris JM, et al. A multi-subunit chlamydial vac-
cine induces antibody and cell-mediated immunity in immunized koalas (Phascolarctos cinereus):
Comparison of three different adjuvants. Am J Reprod Immunol. 2010; 63: 161–72. doi: 10.1111/j.
1600-0897.2009.00776.x PMID: 20064144
5. Khan SA, Waugh C, Kollipara A, Rawlinson G, Brumm J, Nilsson K, et al. Vaccination of koalas (Phas-
colarctos cinereus) with a recombinant chlamydial major outer memebrane protein adjuvanted with
Poly I:C, a host defense peptide and polyphosphazine, elicits strong and long lasting cellular and
humoral immune responses. Vaccine. 2014; 32: 5781–6. doi: 10.1016/j.vaccine.2014.08.037 PMID:
25196393
6. Kollipara A, Wan C, Rawlinson G, Brumm J, Nilsson K, Polkinghorne A, et al. Antigenic specificity of a
monovalent versus polyvalent MOMP based Chlamydia pecorum vaccine in koalas (Phascolarctos
cinereus). Vaccine. 2013; 31: 1217–23. doi: 10.1016/j.vaccine.2012.12.057 PMID: 23306372
7. Kollipara A, Polkinghorne A, Wan C, Kanyoka P, Hanger J, Loader J, et al. Genetic diversity of Chla-
mydia pecorum strains in wild koala locations across Australia and the implications for a recombinant
C. pecorummajor outer membrane protein based vaccine. Vet Microbiol. 2013; 167: 513–22. doi: 10.
1016/j.vetmic.2013.08.009 PMID: 24012135
A Therapeutic Anti-Chlamydial Vaccine for the Koala
PLOS ONE | DOI:10.1371/journal.pone.0146934 January 12, 2016 8 / 9
8. Kollipara A, George C, Hanger J, Loader J, Polkinghorne A, Beagley K, et al. Vaccination of healthy
and diseased koalas (Phascolarctos cinereus) with a Chlamydia pecorummulti-subunit vaccine: Evalu-
ation of immunity and pathology. Vaccine. 2012; 30: 1875–85. doi: 10.1016/j.vaccine.2011.12.125
PMID: 22230583
9. Waugh CA, Timms P, Andrew D, Rawlinson G, Brumm J, Nilsson K, et al. Comparison of subcutaneous
versus intranasal immunization of male koalas (Phascolarctos cinereus) for induction of mucosal and
systemic immunity against Chlamydia pecorum. Vaccine. 2015; 33: 855–60. doi: 10.1016/j.vaccine.
2014.12.052 PMID: 25562793
10. Farris CM, Morrison RP. Vaccination againstChlamydia genital infection utilizing the murineC.muri-
darummodel. Infect Immun. 2011; 79: 986–996. doi: 10.1128/IAI.00881-10 PMID: 21078844
11. Hernandez-Sanchez J, Brumm J, Timms P, Beagley K. Vaccination of koalas with prototype chlamydial
vaccine is safe, and does not increase the incidence of lymphoma-related disease and may be associ-
ated with increased lifespan in captive koalas. Vaccine. 2015; 33: 4459–4463. doi: 10.1016/j.vaccine.
2015.07.029 PMID: 26207589
12. Wan C, Loader J, Hanger J, Beagley KW, Timms P, Polkinghorne A. Using quantitative polymerase
chain reaction to correlate Chlamydia pecorum infectious load with ocular, urinary and reproductive
tract disease in the koala (Phascolarctos cinereus). Aust Vet J. 2011; 89: 409–12. doi: 10.1111/j.1751-
0813.2011.00827.x PMID: 21933169
13. Devereaux LN, Polkinghorne A, Meijer A, Timms P. Molecular evidence for novel chlamydial infections
in the koala (Phascolarctos cinereus). Syst Appl Microbiol. 2003; 26: 245–53. PMID: 12866851
14. Marsh J, Kollipara A, Timms P, Polkinghorne A. Novel molecular markers of Chlamydia pecorum
genetic diversity in the koala (Phascolarctos cinereus). BMCMicrobiol. 2011; 11: 77. doi: 10.1186/
1471-2180-11-77 PMID: 21496349
15. Puls RL, Emery S. Therapeutic vaccination against HIV: Current progress and future possibilities. Clin
Sci. 2006; 110: 59–71. PMID: 16336205
A Therapeutic Anti-Chlamydial Vaccine for the Koala
PLOS ONE | DOI:10.1371/journal.pone.0146934 January 12, 2016 9 / 9
